Analysis of lymphocyte subpopulations in systemic sclerosis

Journal of Investigational Allergology and Clinical Immunology

Volumn 13, Issue 2, 2003, Pages 87-93

  Parolin Ercole, Linete ^a,b   Malvezzi, Mariester ^a   Boaretti, Antonio Carlos ^a   Ramos da Rosa Utiyama, Shirley ^a   Rachid, Acir ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b NONE   (Brazil)

Author keywords

Autoimmunity; Delta; Gamma; Systemic sclerosis; T cells

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CD19 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD71 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN;

ADULT; ARTICLE; B LYMPHOCYTE; BRAZIL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL; PROGNOSIS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE;

ADULT; ANTIBODIES; ANTIGENS, CD45; B-LYMPHOCYTES; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; FEMALE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTE SUBSETS; MALE; NUCLEAR PROTEINS; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SCLERODERMA, SYSTEMIC;

EID: 0042510940     PISSN: 10189068     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Silver, R.M., Miller, K.S. Lung involvement in systemic sclerosis. Rheum Dis Clin North Am 1990, 17:199-216.
2. Black, C.M. Systemic sclerosis "state of art" 1995. Scand J Rheumotol 1995, 24:194-196.
3. White, B. Immunologic aspects of scleroderma. Curr Opin Rheum 1995, 7:541-545.
4. Furst, D.E., Clements, P.J. Hypothesis for the pathogenesis of systemic sclerosis. J Rheumatol 1997, 24:53-57.
5. Gudbjörnsson, B., Hällgren, R., Nettelbladt, A., Gustafsson, R., Mattsson, A., Geijerstam, E., Tötterman, T.H. Phenotypic and functional activation of alveolar macrophages, T lymphocytes and NK cells in patients with systemic sclerosis and primary Sjögren's syndrome. Ann Rheum Dis 1994, 53:574-579.
6. White, B. Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 1996, 22:695-708.
7. Kopinski, P. Use of flow cytometry in evaluation of cellular changes in interstitial lung diseases. Folia Med Cracov 1997, 38:69-115.
8. Domagala-Kulawik, J., Hoser, G., Doboszynska, A., Kawiak, J., Droszcz, W. Interstitial lung disease in systemic sclerosis: comparison of BALF lymphocyte phenotype and DLCO impairment. Respir Med 1998, 92:1295-1301.
9. Czirjak, L., Koncz, A., Varga, I., Devenyi, K., Kumanovics, G., Szues, G. Investigation of the alveolar macrophages and T lymphocytes in 15 patients with systemic sclerosis. Clin Rheumatol 1999, 18:357-363.
10. Bresser, P., Jansen, H.M., Weller, F.R., Lutter, R., Out, T.A. T-cell activation in the lungs of patients with systemic sclerosis and its relation with pulmonary fibrosis. Chest 2001, 120:66S-68S.
11. Sato, S., Hanakawa, H., Hasegawa, M., Nagaoka, T., Hamaguchi, Y., Nishijima, C., Komatsu, K., Hirata, A., Takehara, K. Levels of interleukin 12, a cytokine of type 1 helper T-cells, are elevated in sera from patients with systemic sclerosis. J Rheumatol 2000. 27:2838-2842.
12. Gupta, S., Malayiva, A.N., Rajagopolan, P. Subpopulations of human T lymphocytes. Imbalance of T-cell subpopulations in patients with progressive systemic sclerosis. Clin Exp Immunol 1979, 38:342-347.
13. Alarcón-Segovia, D., Palacios, R., Kasep, G.I. Human postthymic precursor cells in health and disease. Immunoregulatory circuits of the peripheral blood mononuclear cells from patients with progressive systemic sclerosis. J Clin Lab Immunol 1981, 5:143-148.
14. Whiteside, T.L., Kumagai, Y., Roumm, A.D., Almendinger, R., Rodnan, G.P. Suppressor cell function and T lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis. Arthritis Rheum 1983, 26:841-847.
15. Keystone, E.C., Lau, C., Gladman, D.D., Wilkinson, S., Lee, P., Shore, A. Immunoregulatory T-cell subpopulations in patients with scleroderma using monoclonal antibodies. Clin Exp Immunol 1982, 48:443-488.
16. Gustafsson, R., Tötterman, T.H., Klareskog, L., Hällgren, R. Increase in activated T-cells and reduction in suppressor inducer T-cells in systemic sclerosis. Ann Rheum Dis 1990. 49:40-45.
17. Bruns, M., Herrmann, K., Haustein, U.F. Immunologic parameters in systemic sclerosis. Int J Dermatol 1994, 33:25-32.
18. Dalkilic, E., Dilek, K., Gullulu, M., Yavuz, M., Karakoc, Y., Yurtkuran, M., Budak, F., Goral, G. Lymphocyte phenotypes in systemic sclerosis. Ann Rheum Dis 1999, 58:719-720.
19. Masi, A.T., Rodnan, G.P., Medsger Jr., T.A., Altman, R.D., D'Angelo, W.A., Fries, J.F., LeRoy, E.C., Kirsner, A.B., MacKenzie, A.H., McShane, D.J., Myers, A.R., Sharp, G.C. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590.
20. LeRoy, E.C., Black, C., Fleischmajer, R., Jablonska, S., Krieg, T., Medsger Jr., T.A., Rowell, N., Wollheim, F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
21. Holcombe, R.F., Baethge, B.A., Wolf, R.E., Betzing, K.W., Steeart, R.M. Natural killer cells and γδT-cells in scleroderma: relationship to disease duration and anti-Scl-70 antibodies. Ann Rheum Dis 1995, 54:69-72.
22. Tan, E.M., Christia, C., Holman, H.R., Homma, M., Kunkel, H.G., Reichlin, M., Sharp, G.C., Ziff, M., Barnett, E.V. Anti-tissue antibodies in rheumatic disease standardization and nomenclature. Arthritis Rheum 1977, 20:1419-1420.
23. Molden, D.P., Nakamura, R.M., Tan, E.M. Standardization of the immunofluorescence test for autoantibody to nuclear antigens (ANA): use of reference sera of defined antibody specificity. Am J Clin Pathol 1984, 82:57-66.
24. Tan, E.M., Rodnan, G.P., Garcia, I., Moroi, Y., Friysler, M.J., Peebles, C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Arthritis Rheum 1980, 23:617-625.
25. Wilson, M.R., Sanders, R.D. Immunodiffusion assays for antibodies to small nuclear ribonucleoproteins and other cellular antigens. In N.R. Rose, E.C. Macario, J.L. Fahey, H. Friedman, G.M. Penn (Eds.), Manual of clinical laboratory immunology. Washington, American Society for Microbiology, 1992, pp. 741-746.
26. Orfao, A., Buitrago, J.M.G. Detección y cuanfificación de anfígenos celulares. In EA. Ribó (Ed.), La citometría de flujo en el laboratorio clínico. Vigor. Salamanca 1995, pp. 31-51.
27. Frieri, M., Channabasappa, A., Paolano, A., Oster, N., Blau, S.P., Yang, S., Mele, C., Hawrylko, E. Altered T-cell subpopulations and lymphocytes expressing natural killer cell phenotypes in patients with progressive systemic sclerosis. J Allergy Clin Immunol 1991, 87:773-779.
28. Umehara, H., Kumagai, S., Ishida, H., Suginoshita, T., Maeda, M., Imura, H. Enhanced production of interleukin-2 in patients with progressive systemic sclerosis. Hyperactivity of CD4-positive T-cells? Arthritis Rheum 1988, 31:401-407.
29. Postlethwaite, A.E. Early immune events in scleroderma. Rheum Dis Clin North Am 1990, 16:125-139.
30. Dau, P.C., Callahan, J.P. Immune modulation during treatment of systemic sclerosis with plasmapheresis and immunosuppressive drugs. Clin Immunol Immunopathol 1994, 70:159-165.
31. Gerli, R., Agea, E., Bertotto, A. Analysis of T-cells bearing different isotypic forms of the γδ T-cell receptor in patients with systemic autoimmune diseases. J Rheumatol 1991, 18:1504-1510.
32. + T-cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum 1998, 41:327-334.
33. Kahaleh, M.B., Fan, P.S., Otsuka, T. Gammadelta receptor bearing T-cells in scleroderma: enhanced interaction with vascular endothelial cells in vitro. Clin Immunol 1999, 91:188-195.
34. Mitchell, H., Bolster, M.B., LeRoy, E.C. Scleroderma and related conditions. Med Clin North Am 1997, 22:751-764.
35. Rizou, C., Ioannidis, J.P., Panou-Pomonis, E., Sakarellos-Daitsiotis, M., Sakarellos, C., Moutsopoulos, H.M., Vlachoyiannopoulos, P.G. B-cell epitope mapping of DNA topoisomerase I defines epitopes strongly associated with pulmonary fibrosis in systemic sclerosis. Am J Respir Cell Mol Biol 2000, 22:344-351.
36. Fiocco, U., Rosada, M., Cozzi, L., Ortolani, C., De Silvestro, G., Ruffatti, A., Cozzi, E., Gallo, C., Todesco, S. Early phenotypic activation of circulating helper memory T-cells in scleroderma: correlation with disease activity. Ann Rheum Dis 1993, 52:272-277.
37. Kahan, A., Kahan, A., Picard, F., Menkes, C.J., Amor, B. Abnormalities of T lymphocyte subsets in systemic sclerosis demonstrated with anti-CD45RA and anti-CD29 monoclonal antibodies. Ann Rheum Dis 1991, 50:354-358.
38. Sato, S., Hasegawa, M., Fujimoto, M., Tedder, T.F., Takehara, K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000, 165:6635-6643.
39. Tedder, T.F., Sato, S., Poe, J.C., Fujimoto, M. CD19 and CD22 regulate a B lymphocyte signal transduction pathway that contributes to autoimmunity. Keio J Med 2000, 49:1-13.
40. Kantor, T.V., Whiteside, T.L., Friberg, D., Buckingham, R.B., Medsger Jr., T.A. Lymphokine-activated killer cell and natural killer cell activities in patients with systemic sclerosis. Arthritis Rheum 1992, 35:694-699.
41. + com ridotta citotossicitá in una paziente affetta da sclerosi sistemica. Recenti Prog Med 1992, 83:18-20.
42. Miller, E.B., Hiserodt, J.C., Hunt, L.E., Steen, V.D., Medsger Jr., T.A. Reduced natural killer cell activity in patients with systemic sclerosis: correlation with clinical disease type. Arthritis Rheum 1988, 31:1515-1523.